Overenthusiastic interpretation of a nonetheless promising study

10 Apr

A recent study concludes that mesenchymal stem cells (MSC) therapy provides the “same or better” relief for pain and disability, as current gold standard treatments for chronic unspecific low back pain (cLBP) caused by degenerative disc disease (DDD), namely spinal fusion and total disc replacement. This conclusion lacks scientific base, as pointe out in this letter to the Editor.